Evidence map›Paper›PMID 38405208›Full record

Trial reportContemporary oncology (Poznan, Poland)2023

High-dose alectinib for

Rafal Dziadziuszko, Nir Peled, Tony Mok, Solange Peters, Santiago Ponce Aix, Jorge Alatorre-Alexander, Brian D Vicuna, Margaret Maclennan, Vijay Bhagawati-Prasad, Sarah M Shagan and 4 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Contemporary oncology (Poznan, Poland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 7 countries.

Rafal DziadziuszkoDepartment of Oncology and Radiotherapy and Early Clinical Trials Centre, Medical University of Gdańsk, Gdańsk, Poland.
Nir PeledSoroka Medical Centre and Ben-Gurion University, Beer-Sheeva, Israel.
Tony MokState Key Laboratory of Translational Oncology, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong.
Solange PetersLausanne University Hospital, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
Santiago Ponce AixHospital Universitario 12 de Octubre, Madrid, Spain.
Jorge Alatorre-AlexanderHealth Pharma Professional Research, Mexico City, Mexico.
Brian D VicunaComprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
Margaret MaclennanSyneos Health, Edinburgh, UK.
Vijay Bhagawati-PrasadF. Hoffmann-La Roche, Ltd., Welwyn Garden City, UK.
Sarah M ShaganGenentech, Inc., South San Francisco, CA, USA.
Erica SchleifmanGenentech, Inc., South San Francisco, CA, USA.
Thorsten RufF. Hoffmann-La Roche, Ltd., Basel, Switzerland.
Michael S MathisenGenentech, Inc., South San Francisco, CA, USA.
Shirish M GadgeelDepartment of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA.
Chinese University of Hong Kong · HKComprehensive Cancer Centers of Nevada · USGdańsk Medical University · PLHenry Ford Health System · USHospital Universitario 12 De Octubre · ESRoche (Switzerland) · CHRoche (United Kingdom) · GBSoroka Medical Center · ILUniversity Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This paper presents results from Cohort B (rearranged during transfection [ Material and methods: Adults with advanced Results: Among eight treated patients, confirmed best overall responses in evaluable patients were stable disease (4/5) and progressive disease (1/5). One dose-limiting toxicity (death, unknown cause) was considered by the investigator to be related to treatment and underlying disease. Serious adverse events (SAEs) occurred in five patients, and SAEs that may be related to treatment occurred in two patients. Conclusions: Alectinib showed limited activity in advanced

Indexed as

alectinibblood-based assayBlood First Assay Screening Trial (BFAST)circulating tumour DNActDNAliquid biopsyNGSnon-small cell lung cancerNSCLCRET fusion

Identifiers

PMID38405208
PMCPMC10883190
OpenAlexW4391665750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.